Designing Life from Scratch: A Fledgling Field is About to Take Off
By Lisa M. Krieger,
San Jose Mercury News
| 08. 08. 2015
Untitled Document
Mother Nature has always been life's master architect, working off genetic blueprints that are fine-tuned from one generation to the next.
Until now.
Scientists increasingly are designing life from scratch, using inexpensive, fast and accurate tools to create and assemble strands of DNA like tinkertoys -- and instructing cells to do things that nature never imagined.
In industrial clusters in the Bay Area, La Jolla and Boston, the competitive gene-building field is doing for biology what Johannes Gutenberg did for printing -- turning what was once a laborious and uneven artisan effort into affordable and accurate mass production. With the potential to create an industry that could lead to products worth hundreds of billions of dollars, the fast-moving field is not only prompting investor funding but also sparking calls for oversight.
The goal is to build improved medicines, better biofuels and new chemicals -- and perhaps someday splice new genes into sick people, fixing inherited diseases. But the cutting-edge technique also could be used to build dangerous pathogens for warfare.
"We're accelerating genetics," said biochemist Emily Leproust, cofounder...
Related Articles
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Sophie Ryall , BioNews | 08.03.2026
A fertility doctor is being sued for using his own sperm during artificial insemination procedures without the patient's knowledge or consent.
Dr Dennis Lutz used his own sperm repeatedly when treating patient Jean Ann Nelson at the Medical Arts Clinic...